We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Kineta today announced that it has entered into an exclusive option and license agreement with Genentech, Inc., a member of the Roche Group, to develop Kineta's α9/α10 nicotinic acetylcholine receptor (nAChR) antagonists for the treatment of chronic pain.